Stem cell therapy brings new life to musculoskeletal regeneration

Researchers Dr Khay-Yong Saw, Dr Caroline Jee, Ms Amal Dawam, and Ms Alisha Ramlan from the Kuala Lumpur Sports Medicine Centre, Malaysia, and Dr Adam Anz, Andrews Institute, Florida, USA, recently showed how stem cell therapy can be used as a pioneering treatment in articular regeneration of the knee. There is potential to apply this technology to other musculoskeletal damage where there is currently an unmet clinical need, including for patients with damaged articular cartilage, soft tissue, and bone. Now, in a series of case studies, the researchers show exactly how this innovative technology can power musculoskeletal regeneration, from cartilage and soft-tissue repair to the regrowth of heavily damaged bone, in less than a year.

The musculoskeletal system is vital; it protects critical organs, allows movement, and supports the body. However, contrary to its name, it doesn't only consist of muscles and bones. Articular cartilage, as well as tendons and ligaments, are necessary for pain-free and smooth movement in joints such as knees, ankles, and hips. Articular cartilage forms a smooth and lubricated surface where bones meet. Fibrous connective tissue in the form of tendons and ligaments also play an important role, connecting muscle to bone, or bone to bone, respectively.

Yet as with any complex system, the failing of just one component can have long-lasting and deeply felt effects. One example is damage of articular cartilage, either through injury or general wear and tear. In the knee, large cartilage defects can cause pain, swelling, and – in severe cases – loss of mobility. Traditional treatments have limitations. To close the gap on this unmet clinical need, a



Figure 1. a and b: The left ankle joint showing end-stage arthritis (black arrows). c: View after arthroscopic subchondral drilling of almost the entire ankle joint (black arrows). d and e: The same ankle joint, two years following treatment, showing reappearance of the ankle joint

o and e: The same ankle joint, two years following treatment, showing reappearance of the ankle joint space (black arrows).

f: Two years following chondrogenesis, showing good cartilage thickness on both articular surfaces (white arrows).

collaborative team including Dr Khay-Yong Saw, Dr Caroline Jee, Ms Amal Dawam, and Ms Alisha Ramlan from the Kuala Lumpur Sports Medicine Centre, Malaysia, and Dr Adam Anz, Andrews Institute, Florida, USA, demonstrated how stem cell therapy using peripheral blood stem cells (PBSC) can be used to regenerate articular cartilage in the knee, with safe and effective outcomes. So what exactly are PBSC and what is the potential of this innovative technology to treat patients with wide-ranging musculoskeletal damage?

REGENERATIVE POTENTIAL

PBSC are a type of stem cell – a basic and unspecialised cell with the potential to develop (or differentiate) into other types of cells, such as bone and cartilage. PBSC have been shown to have potential to give rise to mesenchymal stem cells, which are especially relevant for musculoskeletal regeneration as they are already primed to differentiate into cartilage cells (chondrocytes) and bone cells (osteoblasts). Their regenerative potential, combined with the ability to readily harvest and process them, make PBSC an excellent candidate to aid musculoskeletal regeneration. What's more, PBSC can be harvested in a large quantity in a single procedure then stored safely for several years, enabling repeat treatments many months after the initial therapy.

Saw explains, 'We believe that the pathway to repair and regeneration of the musculoskeletal system requires three key principles.' Firstly, a fresh injury is created at the damaged site, using subchondral drilling or needling (Figure 1c). PBSC are then injected into the damaged site at repeated intervals, and again after several months, if needed. Finally, functional stimulation is applied to the affected joint. The potential of this innovative technology continues to be harnessed by Saw and collaborators to aid cartilage regeneration, ligament repair, and even bone regeneration following severe open fracture. In doing so, the researchers can address an unmet clinical need for patients with such conditions. With over 980 cases in the last 13 years, we have shown that PBSC can be used safely and effectively for the repair and regeneration of the major components of the musculoskeletal system,' says Saw. Following years of clinical experience and a recent randomised controlled trial in patients with knee cartilage defects, three case studies illustrate the success and broad application of this technology.

FROM KNEE TO ANKLE

Similar to patients with large cartilage knee defects, patients with end-stage ankle arthritis suffer from severe pain, as

drilling, to stimulate the bone marrow. PBSC were then harvested from the patient and injected into the joint alongside hyaluronic acid (HA), a natural fluid that acts as a joint lubricant. The patient then received four injections of PBSC and HA spaced a week apart as well as physiotherapy and joint mobilisation exercises over 12 months. Three PBSC/ HA injections were then given over the course of three weeks at 6-, 12-, 18-, and 24-months post-surgery.

The patient reported appreciable improvement, without adverse postoperative effects. Magnetic resonance imaging (MRI) scans clearly showed cartilage regeneration on both articular surfaces two years after the operation

The potential of this innovative technology continues to be harnessed, aiding cartilage regeneration, ligament repair, and even bone regeneration following severe open fracture. Figure 2. a: The right ankle with an abnormality of the bone and soft tissues in the foot (Haglund deformity, short white arrow), heel inflammation (retrocalcaneal bursitis, black arrow) and painful tendinitis (insertional Achilles tendinopathy, double white arrows). b: The same ankle six years after surgery, showing repair and regeneration of the Achilles tendon (double white arrows). c: Ankle with a Haglund deformity (white arrow). d: The same ankle following arthroscopic treatment (white arrow).

well as a loss of function and mobility. This is caused by the progressive attrition of the joint's articular cartilage and can ultimately lead to bone-on-bone grinding at the surface of the joint. Unsurprisingly, this has a severe impact on normal activities. However, current treatment options for patients with end-stage ankle arthritis are limited and not without complications. Total ankle replacement or fusion of the ankle joint (arthroscopic ankle arthrodesis or open ankle arthrodesis) can provide some respite, but around a quarter of patients experience complications and one fifth require further surgery. For younger patients in particular, these treatments can be deemed as sub-optimal given the patients' longer life expectancy and expectation of a physically active life.

With better treatment options clearly needed, the researchers sought to apply their pioneering articular regeneration technology to patients younger than 60. In one example, a 58-year-old man suffered from advanced ankle arthritis precipitated by a motorcycle accident, resulting in 30 years of ankle pain (Figure 1). He initially underwent keyhole surgery to inspect and drill into the ankle joint using a technique known as subchondral



Saw, et al, Malays Orthop J. 2022, 16(2) doi.org/10.5704/MOJ.2207.022

Lon.

d



Figure 4. Left: Radiographs of the right tibia showing severe fracture of the middle-third of the bone. Right: The same bone, 15 months after surgery, with 13cm of bone growth.

Figure 1d–f), which was in direct contrast to pre-operative images where lack of cartilage due to arthritic changes was apparent (Figure 1a–b).

HEALING THE HEEL

Using a similar approach, Saw and colleagues addressed soft tissue damage in patients with chronic Achilles tendinopathy (CAT). Patients with CAT experience prolonged pain and even disability due to injury to the tendon that attaches the muscle in the lower leg to the heel bone.

In one example, a man aged 59 years underwent surgery to remove calcified loose bodies and a bony growth on the bike cycling after six weeks, once the ankle could bear full weight again. Repeat injections of PBSC and HA were also given three and six months after surgery.

Follow-up MRI scans showed regeneration of the tendon and six years after the treatment the patient was scored as asymptomatic. Jee explains, 'we have shown that autologous PBSC therapy is a safe and effective approach for the repair and regeneration of CAT.'

BONE REGENERATION

Perhaps the most staggering example of musculoskeletal regeneration using PBSC is in the case of bone regeneration in a 16-year-old Grand Prix motorcycle

These case studies highlight the enormous potential of stem cell therapy for the safe and effective regeneration of musculoskeletal tissues.

heel bone (Figure 2). During surgery, multiple needles were inserted into his inflamed Achilles tendon and HA mixed with PBSCs – harvested prior to surgery – were injected into the tendon. Four further identical injections were given at weekly intervals while the patient was sedated. Physiotherapy, electrical nerve stimulation, and joint mobilisation exercises followed directly after surgery. The patient undertook muscle strengthening exercises and stationary rider (Figure 3). Following a high-speed collision, the middle third of the boy's right tibia (shinbone) was severely fractured by damage from an oncoming bike, resulting in fragmented bone as well as severe soft tissue damage.

To treat the patient, bone fragments, foreign matter, and dead tissue were surgically removed and a brace (Ilizarov frame) was fixed to the leg to help lengthen the tibia bone via distraction

osteogenesis or bone growth. Next, PBSC were harvested from the patient and injected into the near and far sites of the fracture. Unfortunately, the near site of the fracture became infected with an antibiotic-resistant infection which meant that bone lengthening could only be performed at the far end of the fracture. Five months of progressive bone lengthening followed until the ends of the bone were prepared for final healing. This involved drilling into the ends of the bone and injecting PBSC. The patient maintained the Ilizarov frame for a further five months, throughout which he underwent a physiotherapy regime, ultrasound, and soft tissue electrical stimulation, as well as joint strengthening and mobilisation exercises. Near-normal nerve activity was recorded 12 months after the injury. At this point, an additional procedure was needed to correct a deformity of the foot and ankle which had developed two months into the bonelengthening procedure. However, just 15 months after his original injury, the patient resumed professional motorbiking.

During the ten months that the patient was supported by the Ilizarov frame, 13cm of bone was regenerated (Figure 4), resulting in a bone healing index (BHI) of 23 days per centimetre. This BHI is favourable compared with previous case studies that report longer BHI (52 days per centimetre), and highlights the effective regeneration seen with PBSC treatment. Saw and colleagues suggest that PBSC perform two vital roles during bone growth. Firstly, that the PBSC themselves differentiate into cells required for bone growth. Secondly, that they release factors that encourage mesenchymal stem cells from the bone marrow to move to the fracture site to aid repair of the musculoskeletal tissues.

PUSHING THE FRONTIERS

These case studies highlight the enormous potential of stem cell therapy for the safe and effective regeneration of musculoskeletal tissues. Patients with severe damage to articular cartilage, soft tissue, and bone have already hugely benefitted from this regenerative technique. Using this innovative approach, it is becoming apparent that surgeons can push the frontiers of medicine for the benefit of patients and bridge the gap of unmet clinical needs within orthopaedics.

Behind the Research



Dr Khay-Yong Saw



Jee

E: <u>enquiry@klsmc.com</u> T: +603 2096 1033



Ms Alisha Ramlan



Dr Adam Anz

E: <u>anz.adam.w@gmail.com</u> T: +1 850 916 8476

Research Objectives

Dr Saw and colleagues use peripheral blood stem cells as a regenerative agent for three broad applications: articular cartilage, bone, and soft tissue.

Ms Ama

Dawam

Detail

Dr Saw, Dr Jee, Ms Amal and Ms Alisha Kuala Lumpur Sports Medicine Centre (KLSMC) 7th Floor, Wisma Perintis 47, Jalan Dungun Damansara Heights 50490 Kuala Lumpur, Malaysia

Dr Anz

Andrews Institute Sports Medicine Orthopedic Surgery 1040 Gulf Breeze Pkwy, Gulf Breeze, Florida 32561, USA

Bio

Dr Khay-Yong Saw is the founder and a consultant orthopaedic surgeon at KLSMC. He specialises in knee joint arthroscopic surgery with stem cells for chondrogenesis together

with bone- and soft-tissue regeneration. He has received numerous awards, publications, and patents for this pioneering technology and for his novel medical devices.

Dr Adam Anz is a consultant orthopaedic surgeon at the Andrews Institute in Pensacola Florida. His clinical and research focus has settled on knee, shoulder, and hip injuries as well as the development of innovative biologic treatments. He is one of the principal investigators for this cartilage regeneration study.

Dr Caroline Jee, CEng, CSci, manages all applied and fundamental research and development activities at KLSMC. She has successfully secured a number of government grants and awards. She has several international patents, is a chartered engineer and chartered scientist.

Ms Amal Dawam is a senior researcher in KLSMC managing research and development projects related to stem cell regeneration. She has more than 15 years' experience in the stem cell industry and undertook cell culture training in Japan. She graduated from Nagoya University, Japan and pursued her MSc at Taylor's University, Malaysia.

Ms Alisha Ramlan is a research assistant who manages all data collection and analysis at KLSMC. She graduated from California State University, Fresno, with a BS in biology. She has more than ten years' experience conducting research and has successfully secured several research grants.

References

- Saw, K-Y, et al, (2022) Chondrogenesis with autologous peripheral blood stem cells for end-stage ankle arthritis: Report of three cases. *Malays Orthop J*, 16(1), 134–7. doi.org/10.5704/MOJ.2203.022
- Saw, K-Y, et al, (2022) Autologous peripheral blood stem cell therapy for chronic Achilles tendinopathy: Report of three cases. *Malays Orthop J*, 16(2), 5. <u>doi.org/10.5704/MOJ.2207.022</u>
- Saw, K-Y, et al, (2021) Arthroscopic subchondral drilling followed by injection of peripheral blood stem cells and hyaluronic acid showed improved outcome compared to hyaluronic acid and physiotherapy for massive knee chondral defects: A randomized controlled trial. Arthroscopy, 37(8), 2502–17.
- Saw, K-Y, et al, (2021) Stem cell-based cartilage regeneration technology, Research Outreach, 127, 90–3. doi.org/10.32907/RO-127-1985367964
- Anz, A, et al, (2021) Mobilized peripheral blood stem cells are pluripotent and can be safely harvested and stored for cartilage repair. Arthroscopy, 37(11), 3347–56.
- Saw, K-Y, et al, (2020) Massive tibial bone regeneration with autologous peripheral blood stem cells using Ilizarov bone transport: A case report. Malays Orthop J, 14(3), doi.10.5704/MOJ.2011.026
- Alkenani, N, et al, (2016) Ilizarov bone transport after massive tibial trauma: Case report, Int J Surg Case Rep, 28, 101–6.
- Saw, K-Y, Jee, C, (2013) From 'Blade Runner' to 'Stem-Cell Player' and beyond. Bone and Joint 360, 2(1), 6–11.
- Saw, K-Y, et al, (2008) Use of radiographic densitometry to predict the bone healing index in distraction osteogenesis. *Malays Orthop J*, 2(1), 44–8. www.morthoj.org/2008v2n1/Radiographic_Densitometry

Personal Response

Do you expect bone regeneration treatment with PBSC to become commonplace within the next decade?

We surely hope so! There are many cases of bone deformity, either due to accident or natural causes. There is currently no ideal treatment for these cases. When PBSC treatment for bone regeneration is commercialised and becomes widely available, these complex cases can be offered an alternative solution. This will lead to a significant improvement in the quality of life for many people.

How else do you foresee PBSC treatment being used?

PBSC treatment is not just limited to musculoskeletal applications. Based on in vitro (laboratory) studies, PBSC have been shown to yield cells from other tissue systems, given the right conditions. We believe that PBSC have regenerative potential that can be harnessed for the repair and regeneration of tissues outside of the musculoskeletal system. We believe that there are applications for cardiovascular regeneration, skin repair, and also wound-healing enhancement.